TRIAL DETAIL
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (DoviGIST)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib (DoviGIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Completed |
|||
Phase: |
2 |
Start Date 01/15/2012 |
Age of Trial (yrs) 12.9 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI) |
|||
Strategy: |
Block KIT + Block blood vessel growth |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
CTKI258AIC02, 2011-001725-24 |
|||
Sponsor: |
Novartis |
|||
Patient Contact: |
Contact: Novartis Pharmaceuticals 862-778-8300 |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
This phase II trial will look at the effectiveness of dovitinib (TKI258) in treating GIST patients that are resistant to imatinib (Glivec). Patients can not have had Sutent or any other targeted treatment except imatinib (second line trial). Dovitinib is a KIT/PDGFRA/VEGFR that also inhibits additional kinases. Dovitinib is made by Novartis. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
Reims |
France |
||||
Milan |
20132 |
Italy |
|||
Barcelona |
08035 |
Spain |
|||
Bordeaux |
33076 |
France |
|||
Lille Cedex |
59020 |
France |
|||
Lyon |
69373 |
France |